Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data
https://www.zacks.com/stock/news/2203052/biotech-stock-roundup-bmy-s-krtx-and-ryzb-acquisition-cytk-surges-on-study-data?cid=CS-ZC-FT-analyst_blog|stock_roundup-2203052
Dec 28, 2023 - Bristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively.
0
TScan: Two 2024 TCR-T Data Readouts Could Bring Significant Value
https://seekingalpha.com/article/4660017-tscan-two-2024-tcr-t-data-readouts-could-bring-significant-value?source=feed_all_articles
Dec 27, 2023 - TScan's results from T-Plex targeting patients with solid tumors in the Phase 1 study are expected to be released in 2024. Read my analysis of TCRX stock.
0
Japan Industrial Production Data Due On Thursday
https://www.rttnews.com/3413610/japan-industrial-production-data-due-on-thursday.aspx?type=alleco
Dec 27, 2023 - Japan will on Thursday release November numbers for industrial production and retail sales, highlighting a busy day for Asia-Pacific economic activity.
0
Mastercard's (MA) SpendingPulse Reveals '23 Holiday Sales Data
https://www.zacks.com/stock/news/2202769/mastercard-s-ma-spendingpulse-reveals-23-holiday-sales-data?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2202769
Dec 27, 2023 - Mastercard's (MA) report reveals E-commerce sales improvement of 6.3% this holiday season while restaurant spending advance 7.8% from the prior-year comparable period. However, spending on electronics took a backseat this time.
0
Cytokinetics gains on positive Phase 3 data for heart disease therapy (update)
https://seekingalpha.com/news/4050439-cytokinetics-stock-gains-data-heart-disease-therapy?source=feed_sector_healthcare
Dec 27, 2023 - Cytokinetics (CYTK) stock surged after positive Phase 3 trial results for its cardiac myosin inhibitor, aficamten, in patients with cardiomyopathy. Read more here.
0
Cytokinetics may be worth $90+ a share in potential deal amid Phase 3 data - UFP
https://seekingalpha.com/news/4050555-cytokinetics-may-be-worth-90-in-potential-acquistion-after-phase-3-data?source=feed_sector_healthcare
Dec 27, 2023 - Cytokinetics may be worth $90/share in a potential takeover after its shares surged 68% on positive Phase 3 trial data for its cardiac myosin inhibitor,...
0
Orthofix (OFIX) Releases New Data for Spinal Fusion Procedures
https://www.zacks.com/stock/news/2202514/orthofix-ofix-releases-new-data-for-spinal-fusion-procedures?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202514
Dec 27, 2023 - According to Orthofix (OFIX), this data highlights the noninvasive and cost-effective nature of SpinalStim, enabling patients to continue their healing in the comfort of their homes.
0
Japan Housing Start Data Due On Wednesday
https://www.rttnews.com/3413513/japan-housing-start-data-due-on-wednesday.aspx?type=alleco
Dec 26, 2023 - Japan will on Wednesday release November numbers for housing starts and construction orders, highlighting a light day for Asia-Pacific economic activity.
0
Oncternal slips after early data for lymphoma therapy
https://seekingalpha.com/news/4050320-oncternal-stock-slips-lymphoma-drug-data?source=feed_sector_healthcare
Dec 26, 2023 - Oncternal Therapeutics (ONCT) shares fell in reaction to initial results from its Phase 1/2 study for CAR T cell therapy in B-cell lymphoma. Read more here.
0
Korea Fund: Accumulate On Stronger Export Data
https://seekingalpha.com/article/4659591-korea-fund-accumulate-on-stronger-export-data?source=feed_tag_etf_portfolio_strategy
Dec 25, 2023 - The Korea Fund's discount to NAV remains favorable, and South Korea trades at a substantial discount to India and Taiwan. Find out why KF fund's discount is very attractive.
0